Title
Nicotinamide Mononucleotide Is Safely Metabolized and Significantly Reduces Blood Triglyceride Levels in Healthy Individuals
Background
The increase in nicotinamide adenine dinucleotide (NAD+) levels by consuming nicotinamide mononucleotide (NMN) has been linked to positive effects on age-related diseases and general health. While the safety of orally ingesting NMN has been established, uncertainties persist regarding the safety and effectiveness of administering NMN intravenously in humans. To fill this gap in understanding, we conducted a study involving 10 healthy volunteers to examine the safety of intravenous NMN administration. The results showed no detrimental effects on essential health indicators, affirming the safety of administering NMN intravenously in human subjects.
Methods
To assess the safety of administering nicotinamide mononucleotide (NMN) intravenously, a study was conducted with the participation of 10 healthy volunteers. Following the infusion of NMN, a comprehensive monitoring approach was employed, which included the examination of various health parameters such as electrocardiograms, pulse, blood pressure, and metabolic markers in vital organs (liver, heart, pancreas, and kidneys). Furthermore, the study involved measuring blood levels of nicotinamide adenine dinucleotide (NAD+) and triglycerides (TG) to evaluate the impact of intravenous NMN administration on these critical indicators.
Results
The intravenous administration of nicotinamide mononucleotide (NMN) to 10 healthy volunteers demonstrated safety, as evidenced by the absence of adverse effects on electrocardiograms, pulse, blood pressure, or metabolic markers in vital organs. Noteworthy is the substantial increase in blood nicotinamide adenine dinucleotide (NAD+) levels without any observed harm to blood cells resulting from NMN administration. Additionally, the study unveiled a significant reduction in blood triglyceride (TG) levels subsequent to NMN administration. These findings imply the safety and potential therapeutic advantages of intravenous NMN administration, especially in the context of preventing and treating conditions linked to elevated TG levels, such as fatty liver and diabetes.
Conclusion
The results of the study confirm the safety of administering nicotinamide mononucleotide (NMN) intravenously in a cohort of 10 healthy volunteers. The absence of adverse effects on crucial health indicators, alongside a noteworthy rise in blood nicotinamide adenine dinucleotide (NAD+) levels and a reduction in blood triglyceride (TG) levels, underscores the potential of intravenous NMN administration in both the prevention and treatment of conditions associated with elevated TG levels. These findings offer valuable insights into the safety and potential therapeutic uses of NMN in the context of human health, contributing to the ongoing exploration of strategies aimed at promoting healthy aging and addressing age-related diseases.